VBI Vaccines up on U.S. launch of hepatitis B vaccine

VBI Vaccines

29/03/2022 14:57

** Shares of vaccine developer  VBIV.O  up ~10% at $1.74
    ** Co says its hepatitis B vaccine, PreHevbrio, is now
available in the United States for the prevention of infection
caused by all known subtypes of hepatitis B virus in adults age
18 years and older  urn:newsml:reuters.com:*:nBw7s22Gra
    ** PreHevbrio was approved by the U.S. FDA in November 2021
    ** This launch coincides with the swell of momentum
following a CDC advisory committtee's decision to include
PreHevbrio in its list of recommended adult HBV vaccines - VBIV
    ** Up to Monday's close, shares of VBIV down ~32.5% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; +91  8061822700;))